Tafamidis for the treatment of transthyretin-associated familial amyloid polyneuropathy

Bibliography

• Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75:408-27
   PubMed Web of Science ®Google Scholar
• Costa PP, Figueira AS, Bravo FR. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA 1978;75:4499-503
   PubMed Web of Science ®Google Scholar
• Mita S, Maeda S, Shimada K, Araki S. Analyses of prealbumin mRNAs in individuals with familial amyloidotic polyneuropathy. J Biochem 1986;100:1215-22
   PubMedGoogle Scholar
• Blake CC, Geisow MJ, Oatley SJ, et al. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol 1978;121:339-56
   PubMed Web of Science ®Google Scholar
• Hammarstrom P, Jiang X, Hurshman AR, et al. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 2002;99(Suppl 4):16427-32
   PubMedGoogle Scholar
• Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008;14:3219-30
   PubMed Web of Science ®Google Scholar
• Johnson SM, Connelly S, Fearns C, et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 2012;421:185-203
   PubMed Web of Science ®Google Scholar
• Sousa MM, Cardoso I, Fernandes R, et al. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001;159:1993-2000
   PubMed Web of Science ®Google Scholar
• Andersson K, Olofsson A, Nielsen EH, et al. Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun 2002;294:309-14
   PubMed Web of Science ®Google Scholar
• Reixach N, Deechongkit S, Jiang X, et al. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 2004;101:2817-22
   PubMed Web of Science ®Google Scholar
• Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011;10:1086-97
   PubMed Web of Science ®Google Scholar
• ORPHANET. Prevalence of rare diseases: Bibliographic data. 12 A.D. Nov. Report No.: 1
   Google Scholar
• Connors LH, Lim A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160-84
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2013;34:520-8
   PubMed Web of Science ®Google Scholar
• Blevins G, Macaulay R, Harder S, et al. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology 2003;60:1625-30
   PubMed Web of Science ®Google Scholar
• Levy J, Hawkins PN, Rowczenio D, et al. Familial amyloid polyneuropathy associated with the novel transthyretin variant Arg34Gly. Amyloid 2012;19:201-3
   PubMed Web of Science ®Google Scholar
• Benson MD, Cohen AS. Generalized amyloid in a family of Swedish origin. A study of 426 family members in seven generations of a new kinship with neuropathy, nephropathy, and central nervous system involvement. Ann Intern Med 1977;86:419-24
   PubMed Web of Science ®Google Scholar
• Tawara S, Nakazato M, Kangawa K, et al. Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun 1983;116:880-8
   PubMed Web of Science ®Google Scholar
• Holmgren G, Holmberg E, Lindstrom A, et al. Diagnosis of familial amyloidotic polyneuropathy in Sweden by RFLP analysis. Clin Genet 1988;33:176-80
   PubMed Web of Science ®Google Scholar
• Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 1995;60:512-21
   PubMed Web of Science ®Google Scholar
• Plante-Bordeneuve V, Carayol J, Ferreira A, et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 2003;40:e120
   PubMed Web of Science ®Google Scholar
• Coutinho P, Da Silva AM, Lima JL, Barbosa AR. Forty years of experience with type I amyloid neuropathy: review of 483 cases. In: Glenner GG, Costa PP, Falcao de Freitas A, editors. Amyloid and Amyloidosis. amsterdam; 1980. p. 88-98
   Google Scholar
• Conceicao I. Clinical features of TTR-FAP in Portugal. Amyloid 2012;19(Suppl 1):71-2
   PubMedGoogle Scholar
• Holmgren G, Costa PM, Andersson C, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994;31:351-4
   PubMed Web of Science ®Google Scholar
• Hellman U, Alarcon F, Lundgren HE, et al. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008;15:181-6
   PubMed Web of Science ®Google Scholar
• Jacobson DR, Gertz MA, Buxbaum JN. Transthyretin VAL107, a new variant associated with familial cardiac and neuropathic amyloidosis. Hum Mutat 1994;3:399-401
   PubMedGoogle Scholar
• Plante-Bordeneuve V, Ferreira A, Lalu T, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007;69:693-8
   PubMed Web of Science ®Google Scholar
• Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991;40:242-6
   PubMed Web of Science ®Google Scholar
• Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77:64-71
   PubMed Web of Science ®Google Scholar
• Suhr OB, Friman S, Ericzon BG. Early liver transplantation improves familial amyloidotic polyneuropathy patients' survival. Amyloid 2005;12:233-8
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012;78:637-43
   PubMed Web of Science ®Google Scholar
• Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000;123(Pt 7):1495-504
   PubMed Web of Science ®Google Scholar
• Liepnieks JJ, Benson MD. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 2007;14:277-82
   PubMed Web of Science ®Google Scholar
• Yazaki M, Mitsuhashi S, Tokuda T, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007;7:235-42
   PubMed Web of Science ®Google Scholar
• Ihse E, Suhr OB, Hellman U, Westermark P. Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med (Berl) 2011;89:171-80
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Sekijima Y, et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid 2012;19(Suppl 1):37-8
   PubMedGoogle Scholar
• Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 2012;101:805-13
   PubMed Web of Science ®Google Scholar
• Adams D. Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord 2013;6:129-39
   PubMed Web of Science ®Google Scholar
• Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012;19(Suppl 1):43-4
   PubMed Web of Science ®Google Scholar
• Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012;19(Suppl 1):34-6
   PubMedGoogle Scholar
• Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012;109:9629-34
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da SA, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785-92
   PubMed Web of Science ®Google Scholar
• Peripheral Nerve Society. Diabetic polyneuropathy in controlled clinical trials: consensus Report of the European Assessment. Ann Neurol 1995;38:478-82
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997;49:229-39
   PubMed Web of Science ®Google Scholar
• Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000;284:2215-21
   PubMed Web of Science ®Google Scholar
• Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 2005;7:497-508
   PubMedGoogle Scholar
• European Medicines Agency (EMA). Vyndaqel (R) Assessment Report. 2011
   Google Scholar
• Lozeron P, Theaudin M, Mincheva Z, et al. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol 2013
   PubMedGoogle Scholar
• Plante-Bordeneuve V, Suhr OB, Maurer MS, et al. The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin 2013;29:77-84
   PubMed Web of Science ®Google Scholar